Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa and in the United States of America. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties within the urogenital therapeutic area and of treatments for rare diseases. Consolidated revenue for 2015 was € 1,047.7 million, operating income was € 278.5 million and net income was € 198.8 million.

HQMilano, IT
Cybersecurity ratingFMore
Recordati was founded in 1926 and is headquartered in Milano, IT

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Recordati

Fritz Squindo

Fritz Squindo

Enrico Baroncia

Enrico Baroncia

General Manager Pharmaceuticals Italy
Gabriele Finzi

Gabriele Finzi

VP Corporate Development & Licensing
Daria Ghidoni

Daria Ghidoni

VP Corporate Legal Counsel
Giuseppe Gualazzini

Giuseppe Gualazzini

Senior VP Group Human Resources
Giovanni Minora

Giovanni Minora

Director Corporate Auditing
Show more

Recordati Office Locations

Recordati has an office in Milano
Milano, IT (HQ)
Via Matteo Civitali, 1
Show all (1)

Recordati Financials and Metrics

Summary Metrics

Founding Date


Recordati Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Recordati Online and Social Media Presence

Embed Graph

Recordati News and Updates

Recordati Rare Diseases, Inc. Announces Transfer of U.S. Marketing Rights to SIGNIFOR® (pasireotide) Injection and SIGNIFOR LAR® (pasireotide) for Injectable Suspension

LEBANON, N.J., Feb. 20, 2020 /PRNewswire/ -- Recordati Rare Diseases, Inc., a biopharmaceutical company committed to providing orphan therapies to underserved rare disease communities in the U.S., today announced the transfer of U.S. marketing rights to SIGNIFOR® (pasireotide) injection...

Recordati to seek Canadian approval for kidney disease drug

Italy's Recordati said on Tuesday it plans to seek Canadian approval for its drug Cystagon, which treats a rare kidney disease, in a potential blow to Horizon Pharma,, which makes the only drug approved for treatment in Canada.

CVC Capital revs up rare disease ambitions with $3.5B Recordati buyout

Recordati has finally sealed a sale. Private equity player CVC Capital Partners agreed to drop €3.03 billion ($3.5 billion) on a 51.8% controlling stake, aiming to use its own connections to help beef up Recordati's orphan and specialty care business.

CVC weighs $3B-plus Recordati buy, but family and political drama could scuttle talks: FT

Italy’s Recordati has long been weighing a sale, and things may now be getting serious. Private equity player CVC is in advanced talks to pick up a controlling stake—worth more than €3 billion—from the billionaire Recordati family, the Financial Times reports.

Recordati Frequently Asked Questions

  • When was Recordati founded?

    Recordati was founded in 1926.

  • Who are Recordati key executives?

    Recordati's key executives are Fritz Squindo, Enrico Baroncia and Gabriele Finzi.

  • How many employees does Recordati have?

    Recordati has 1,998 employees.

  • Who are Recordati competitors?

    Competitors of Recordati include BERLIN-CHEMIE, BiosPacific and Douglas Pharmaceuticals.

  • Where is Recordati headquarters?

    Recordati headquarters is located at Via Matteo Civitali, 1, Milano.

  • Where are Recordati offices?

    Recordati has an office in Milano.

  • How many offices does Recordati have?

    Recordati has 1 office.